GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

Dr_Monkeybreath Dec. 4 at 2:42 PM

$GTBP 8,000 @ .735. 🍽️

0 · Reply

DaBullRunner Dec. 4 at 2:00 PM

$GTBP watching … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

never2much Dec. 4 at 12:26 PM

$GTBP Their commercial is also on Fox Business, was just on.

0 · Reply

NathanNat Dec. 4 at 2:51 AM

$GTBP it dropped cause we are getting diluted again. Did anyone see they actually advertised on CNBC today?

0 · Reply

PAS_Trader Dec. 3 at 9:31 PM

$GTBP be ready for another 20% down tomorrow

0 · Reply

Kaynoshi Dec. 3 at 9:31 PM

$GTBP 🤔

0 · Reply

Miketom72 Dec. 3 at 8:47 PM

$GTBP definitely not a typical day, volume was unusual Anyone with an opinion?

1 · Reply

Kaynoshi Dec. 3 at 8:14 PM

$GTBP damn is it dead?

0 · Reply

Dr_Monkeybreath Dec. 2 at 2:37 PM

$GTBP

0 · Reply

StockFlips Nov. 27 at 12:47 PM

Raise your hand if November was insane for you..? Bear or Bull. Wild volatility and now a massive V recovery. But, does the bull market continue? Here is a look at $SPY A retrace to support level 1 with a bounce is a strong indicator the bull market continues. A retrace to support level 2 signals a 50/50 chance, but at that point is creating a right hand shoulder (head and shoulders pattern). A downside break below 660 signals extreme caution for the bulls. 650 break signals the start of a bear market. I’m still rooting for the bulls. This year a Santa rally is required to maintain a longer term bull market. Likely the most crucial year yet based on the chart and over-valuations outside of the Mag 7… $SMX $ITRM $GTBP $RIVN

1 · Reply

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 14, 2025, 9:00 AM EST - 20 days ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:05 PM EDT - 4 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 4 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 6 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 7 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 10 months ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Mar 28, 2022, 4:15 PM EDT - 4 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 9, 2022, 4:24 PM EST - 4 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 3, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Feb 24, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 18, 2022, 7:30 AM EST - 4 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Dr_Monkeybreath Dec. 4 at 2:42 PM

$GTBP 8,000 @ .735. 🍽️

0 · Reply

DaBullRunner Dec. 4 at 2:00 PM

0 · Reply

never2much Dec. 4 at 12:26 PM

$GTBP Their commercial is also on Fox Business, was just on.

0 · Reply

NathanNat Dec. 4 at 2:51 AM

$GTBP it dropped cause we are getting diluted again. Did anyone see they actually advertised on CNBC today?

0 · Reply

PAS_Trader Dec. 3 at 9:31 PM

$GTBP be ready for another 20% down tomorrow

0 · Reply

Kaynoshi Dec. 3 at 9:31 PM

$GTBP 🤔

0 · Reply

Miketom72 Dec. 3 at 8:47 PM

$GTBP definitely not a typical day, volume was unusual Anyone with an opinion?

1 · Reply

Kaynoshi Dec. 3 at 8:14 PM

$GTBP damn is it dead?

0 · Reply

Dr_Monkeybreath Dec. 2 at 2:37 PM

$GTBP

0 · Reply

StockFlips Nov. 27 at 12:47 PM

1 · Reply

SmartMoneyTradez Nov. 26 at 8:13 PM

$ADTX $SLRX $GTBP $MSGM Short squeeze watch for today. No real breakout volume. ADTX looked good

1 · Reply

Dr_Monkeybreath Nov. 26 at 7:03 PM

$GTBP 10% gains are cool, but this could go 1000% if the science works. PT is $8.00 for a reason. 🚀

0 · Reply

gamblininvestor1 Nov. 26 at 6:39 PM

$GTBP I just saw a commercial on Bloomberg channel about this and here I am.

0 · Reply

StockFlips Nov. 26 at 5:47 PM

$GTBP 10% now .80s

1 · Reply

i_like_bb_stock Nov. 26 at 5:42 PM

$GTBP going for 80s, nice swing so far

0 · Reply

Dr_Monkeybreath Nov. 26 at 5:10 PM

$GTBP feels like the people controlling this took an early holiday. be curious to see how if moves if more buyers show up.🤔

0 · Reply

lucasbrennan902 Nov. 26 at 10:41 AM

$GTBP

0 · Reply

calderinho Nov. 26 at 10:09 AM

$GTBP

0 · Reply

masonRhiiine Nov. 26 at 10:04 AM

GT Biopharma looks set for a busy few months $GTBP GTB-5550 IND submission expected in 4Q25. Funded through the end of 1Q26 with 6 assets in the preclinical development pipeline. They should have some news flow before they need to raise again or good news could get them into a situation where a competitor takes them out for a premium.

0 · Reply

william64 Nov. 26 at 12:03 AM

$GTBP who’s paying for all the tv ads?

0 · Reply

william64 Nov. 26 at 12:02 AM

$GTBP lol. No revs, 1 employee. In business since 1965?

0 · Reply

Dr_Monkeybreath Nov. 25 at 4:32 PM

$GTBP more big bids keep creeping up. trying to be slick, but they really want these shares...😏

0 · Reply

Market Cap	8.04M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,567,400
Avg Vol	2,500,966
Day's Range	N/A - N/A
Shares Out	10.64M
Stochastic %K	20%
Beta	1.52
Analysts	Sell
Price Target	$8.00